Sachar Ryan, Lee Tony Y, DiAntonio Aaron, Dy Christopher J, Wever Jason, Milbrandt Jeff, Brogan David M
Department of Orthopedic Surgery, Washington University in St. Louis, St. Louis, MO.
Department of Genetics, Washington University in St. Louis, St. Louis, MO.
J Hand Surg Am. 2025 Jan 29. doi: 10.1016/j.jhsa.2024.12.009.
Sterile alpha and TlR motif containing-1 (SARM1) protein has been demonstrated to play a critical role in the initiation of Wallerian degeneration after nerve injury. The goal of this study was to assess whether blockade of SARM1 activity inhibits Wallerian degeneration following nerve transection, potentially promoting more rapid recovery of axonal function.
An adeno-associated virus plasmid encoded with a dominant-negative SARM1 protein fused with green fluorescent protein to impair SARM1 function, was injected into 24 juvenile rats to create a SARM1 dominant-negative (SARM1-DN) phenotype. Twenty-four control rats were injected with a control plasmid expressing only green fluorescent protein. Three weeks after transfection, the rats underwent unilateral sciatic nerve transection and repair. Walking track analysis and nonsurvival surgeries were performed at 2 days, 2 weeks, or 6 weeks to assess muscle strength and compound nerve action potential. Histomorphologic and electrodiagnostic studies were evaluated with mixed-effect analysis.
Histomorphologic analysis showed maintenance of axons in the SARM1-DN animals at 2 weeks, with significantly improved compound nerve action potential amplitude. Muscle testing demonstrated greater gastrocnemius strength in SARM1 DN muscles at 2 days and 2 weeks compared to controls, although this was not maintained at 6 weeks.
Inhibition of SARM1 resulted in early increases in number and myelination of axons and action potential after sciatic nerve transection and repair in SARM1-DN rats.
SARM1 inhibition may offer the potential to delay Wallerian degeneration following nerve transection and enable earlier functional recovery of motor strength. .
含无菌α和TIR基序-1(SARM1)蛋白已被证明在神经损伤后沃勒变性的起始过程中起关键作用。本研究的目的是评估阻断SARM1活性是否能抑制神经横断后的沃勒变性,从而可能促进轴突功能更快恢复。
将编码与绿色荧光蛋白融合的显性负性SARM1蛋白的腺相关病毒质粒注入24只幼年大鼠,以产生SARM1显性负性(SARM1-DN)表型。24只对照大鼠注射仅表达绿色荧光蛋白的对照质粒。转染三周后,对大鼠进行单侧坐骨神经横断和修复。在术后2天、2周或6周进行行走轨迹分析和非存活手术,以评估肌肉力量和复合神经动作电位。采用混合效应分析对组织形态学和电诊断研究进行评估。
组织形态学分析显示,SARM1-DN组动物在2周时轴突得以保留,复合神经动作电位幅度显著改善。肌肉测试表明,与对照组相比,SARM1-DN组肌肉在术后2天和2周时腓肠肌力量更大,尽管在6周时未保持这一优势。
在SARM1-DN大鼠中,抑制SARM1可导致坐骨神经横断和修复后轴突数量、髓鞘形成以及动作电位的早期增加。
抑制SARM1可能具有延缓神经横断后沃勒变性并使运动力量更早恢复功能的潜力。